Lipid accumulation product and visceral adiposity index in polycystic ovary syndrome: a systematic review and meta-analysis of observational studies.

IF 3.9 2区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Lipids in Health and Disease Pub Date : 2025-10-07 DOI:10.1186/s12944-025-02719-y

Mohammadamin Parsaei, Elaheh Karimi, Amirali Barkhordarioon, Mohammadreza Yousefi, Azadeh Tarafdari

{"title":"Lipid accumulation product and visceral adiposity index in polycystic ovary syndrome: a systematic review and meta-analysis of observational studies.","authors":"Mohammadamin Parsaei, Elaheh Karimi, Amirali Barkhordarioon, Mohammadreza Yousefi, Azadeh Tarafdari","doi":"10.1186/s12944-025-02719-y","DOIUrl":null,"url":null,"abstract":"Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder associated with reproductive and metabolic dysfunction. Emerging evidence indicates that the lipid accumulation product (LAP) and visceral adiposity index (VAI) could be valuable indicators for evaluating metabolic dysfunction. This study aims to compare LAP and VAI between women with PCOS and healthy controls to evaluate their potential role in metabolic risk assessment.Methods: A structured database search was carried out on March 18, 2025, using PubMed, Web of Science, Scopus, and Embase. Observational studies comparing LAP/VAI levels between women with PCOS and healthy controls were included. Risk of bias was assessed using the Joanna Briggs Institute checklists. A random-effects meta-analysis was carried out to evaluate the pooled differences in LAP and VAI levels between individuals with PCOS and those in the control group. Subgroup analyses were conducted based on the PCOS phenotypes (A, B, C, and D) defined by the Rotterdam criteria and the body mass index categories (lean and overweight/obese).Results: Fifty studies (13,741 women) were analyzed, with 41 included in the meta-analysis. LAP (32 studies: Cohen's d = 0.597 [0.469-0.726]; P-value < 0.001; I2 = 88.22%) and VAI (28 studies: Cohen's d = 0.457 [0.378-0.537]; P-value < 0.001; I2 = 65.16%) were significantly higher in PCOS women, with calculated pooled values of 37.1 vs. 23.9 and 3.1 vs. 2.6, respectively. Subgroup analyses revealed that LAP lost significance across all phenotypes (P-value > 0.05), while VAI remained elevated in phenotypes A (P-value < 0.001), B (P-value = 0.001), and D (P-value = 0.001), with marginal significance in C (P-value = 0.051). Stratified by body mass index, LAP was non-significant in lean women (P-value = 0.083) but higher in overweight/obese women (P-value = 0.001). Conversely, VAI was significantly elevated in both lean and overweight/obese groups (P-value = 0.001 each).Conclusions: This study demonstrates significantly higher levels of LAP and VAI in patients with PCOS compared to controls. These readily calculable indices may serve as practical tools for metabolic risk stratification in PCOS populations. However, further research is needed to establish their diagnostic accuracy and validate their clinical utility.","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"311"},"PeriodicalIF":3.9000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506430/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lipids in Health and Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12944-025-02719-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder associated with reproductive and metabolic dysfunction. Emerging evidence indicates that the lipid accumulation product (LAP) and visceral adiposity index (VAI) could be valuable indicators for evaluating metabolic dysfunction. This study aims to compare LAP and VAI between women with PCOS and healthy controls to evaluate their potential role in metabolic risk assessment.

Methods: A structured database search was carried out on March 18, 2025, using PubMed, Web of Science, Scopus, and Embase. Observational studies comparing LAP/VAI levels between women with PCOS and healthy controls were included. Risk of bias was assessed using the Joanna Briggs Institute checklists. A random-effects meta-analysis was carried out to evaluate the pooled differences in LAP and VAI levels between individuals with PCOS and those in the control group. Subgroup analyses were conducted based on the PCOS phenotypes (A, B, C, and D) defined by the Rotterdam criteria and the body mass index categories (lean and overweight/obese).

Results: Fifty studies (13,741 women) were analyzed, with 41 included in the meta-analysis. LAP (32 studies: Cohen's d = 0.597 [0.469-0.726]; P-value < 0.001; I² = 88.22%) and VAI (28 studies: Cohen's d = 0.457 [0.378-0.537]; P-value < 0.001; I² = 65.16%) were significantly higher in PCOS women, with calculated pooled values of 37.1 vs. 23.9 and 3.1 vs. 2.6, respectively. Subgroup analyses revealed that LAP lost significance across all phenotypes (P-value > 0.05), while VAI remained elevated in phenotypes A (P-value < 0.001), B (P-value = 0.001), and D (P-value = 0.001), with marginal significance in C (P-value = 0.051). Stratified by body mass index, LAP was non-significant in lean women (P-value = 0.083) but higher in overweight/obese women (P-value = 0.001). Conversely, VAI was significantly elevated in both lean and overweight/obese groups (P-value = 0.001 each).

Conclusions: This study demonstrates significantly higher levels of LAP and VAI in patients with PCOS compared to controls. These readily calculable indices may serve as practical tools for metabolic risk stratification in PCOS populations. However, further research is needed to establish their diagnostic accuracy and validate their clinical utility.

查看原文本刊更多论文

多囊卵巢综合征的脂质积累产物和内脏脂肪指数：观察性研究的系统回顾和荟萃分析。

背景：多囊卵巢综合征（PCOS）是一种常见的与生殖和代谢功能障碍相关的内分泌疾病。越来越多的证据表明，脂质积累产物（LAP）和内脏脂肪指数（VAI）可能是评估代谢功能障碍的有价值的指标。本研究旨在比较PCOS女性与健康对照者的LAP和VAI，以评估其在代谢风险评估中的潜在作用。方法：于2025年3月18日使用PubMed、Web of Science、Scopus、Embase等数据库进行结构化检索。观察性研究比较多囊卵巢综合征妇女和健康对照之间的LAP/VAI水平。偏见风险是用乔安娜布里格斯研究所的清单来评估的。采用随机效应荟萃分析评估PCOS患者与对照组之间LAP和VAI水平的综合差异。根据鹿特丹标准定义的PCOS表型（A、B、C和D）和体重指数类别（瘦和超重/肥胖）进行亚组分析。结果：50项研究（13741名女性）被分析，其中41项被纳入meta分析。PCOS女性的LAP（32项研究：Cohen’s d = 0.597 [0.469-0.726]； p值2 = 88.22%）和VAI（28项研究：Cohen’s d = 0.457 [0.378-0.537]； p值2 = 65.16%）显著高于PCOS女性，计算合并值分别为37.1 vs. 23.9和3.1 vs. 2.6。亚组分析显示，LAP在所有表型中都失去了显著性（p值>.05），而VAI在表型A中仍然升高(p值结论：本研究表明，PCOS患者的LAP和VAI水平明显高于对照组。这些易于计算的指标可作为多囊卵巢综合征人群代谢风险分层的实用工具。然而，需要进一步的研究来建立其诊断准确性和验证其临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lipids in Health and Disease 生物-生化与分子生物学

CiteScore

7.70

自引率

2.20%

发文量

122

审稿时长

3-8 weeks

期刊介绍： Lipids in Health and Disease is an open access, peer-reviewed, journal that publishes articles on all aspects of lipids: their biochemistry, pharmacology, toxicology, role in health and disease, and the synthesis of new lipid compounds. Lipids in Health and Disease is aimed at all scientists, health professionals and physicians interested in the area of lipids. Lipids are defined here in their broadest sense, to include: cholesterol, essential fatty acids, saturated fatty acids, phospholipids, inositol lipids, second messenger lipids, enzymes and synthetic machinery that is involved in the metabolism of various lipids in the cells and tissues, and also various aspects of lipid transport, etc. In addition, the journal also publishes research that investigates and defines the role of lipids in various physiological processes, pathology and disease. In particular, the journal aims to bridge the gap between the bench and the clinic by publishing articles that are particularly relevant to human diseases and the role of lipids in the management of various diseases.